METX

Healthcare CA METX

1.99CAD
0.00(0%)

Last update at 2026-06-23T13:30:00Z

Day Range

1.991.99

LowHigh

52 Week Range

2.0010.40

LowHigh

Fundamentals

Previous Close 1.99
Market Cap75.12M
Volume0
P/E Ratio-
Dividend Yield-%
EBITDA-1.31540M
Revenue TTM0.00000M
Revenue Per Share TTM-
Gross Profit TTM 0.00000M
Diluted EPS TTM-0.04

Overview
Financials
Peer Comparison
Reports
Stock Research & News
Profile

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown	2025-09-30	2024-09-30	2023-09-30	2022-09-30
Type	yearly	yearly	yearly	yearly
Date	2025-09-30	2024-09-30	2023-09-30	2022-09-30
Income before tax	-1.19320M	-1.29464M	-6.52039M	-0.14578M
Minority interest	-	-	-	-
Net income	-1.19320M	-1.29464M	-6.52039M	-0.14578M
Selling general administrative	0.78M	1.06M	0.95M	0.10M
Selling and marketing expenses	-	-	-	-
Gross profit	-	-	-	-
Reconciled depreciation	0.08M	-	-	-
Ebit	-	-	-	-
Ebitda	-	-	-	-
Depreciation and amortization	-	-	-	-
Non operating income net other	-	-	-	-
Operating income	-1.21829M	-1.37323M	-6.55180M	-0.16278M
Other operating expenses	-	-	-	-
Interest expense	0.01M	0.00000M	0.00746M	0.01M
Tax provision	-	-	-	-
Interest income	0.04M	0.03M	0.01M	-
Net interest income	0.03M	-	-	-
Extraordinary items	-	-	-	-
Non recurring	-	-	-	-
Other items	-	-	-	-
Income tax expense	-	-	-	-
Total revenue	0.00000M	0.00000M	0.00000M	0.00000M
Total operating expenses	1.22M	-	-	-
Cost of revenue	-	-	-	-
Total other income expense net	-	-	-	-
Discontinued operations	-	-	-	-
Net income from continuing ops	-1.19320M	-	-	-
Net income applicable to common shares	-	-1.29464M	-6.52039M	-0.14578M
Preferred stock and other adjustments	-	-	-	-

Breakdown	2025-09-30	2024-09-30	2023-09-30	2022-09-30
Type	yearly	yearly	yearly	yearly
Date	2025-09-30	2024-09-30	2023-09-30	2022-09-30
Total assets	1.76M	1.54M	0.67M	0.10M
Intangible assets	-	0.00000M	0.00000M	0.00000M
Earning assets	-	-	-	-
Other current assets	-	-	-	-
Total liab	0.26M	0.06M	0.15M	0.23M
Total stockholder equity	1.50M	1.48M	0.52M	-0.13148M
Deferred long term liab	-	-	-	-
Other current liab	-	-	-	-
Common stock	-	6.11M	4.56M	0.51M
Capital stock	8.59M	-	-	-
Retained earnings	-9.72870M	-4.63614M	-4.03240M	-0.66283M
Other liab	-	-	-	-
Good will	-	-	-	-
Other assets	-	-	-	-
Cash	1.35M	1.50M	0.65M	0.08M
Cash and equivalents	-	-	-	-
Total current liabilities	0.25M	0.06M	0.15M	0.17M
Current deferred revenue	-	-	-	-
Net debt	-	-	-	-
Short term debt	-	0.00000M	0.00000M	0.13M
Short long term debt	-	-	-	-
Short long term debt total	-	-	-	-
Other stockholder equity	-	-	0.00000M	0.02M
Property plant equipment	-	0.00016M	0.00020M	0.00025M
Total current assets	1.50M	1.54M	0.67M	0.10M
Long term investments	-	-	-	-
Net tangible assets	-	-	-	-
Short term investments	0.06M	-	-	-
Net receivables	-	-	-	-
Long term debt	-	-	0.00000M	0.06M
Inventory	-	-	-	-
Accounts payable	0.16M	-	-	-
Total permanent equity	-	-	-	-
Noncontrolling interest in consolidated entity	-	-	-	-
Temporary equity redeemable noncontrolling interests	-	-	-	-
Accumulated other comprehensive income	-	-	-	-
Additional paid in capital	-	-	-	-
Common stock total equity	-	-	-	-
Preferred stock total equity	-	-	-	-
Retained earnings total equity	-	-	-	-
Treasury stock	-	-	-	-
Accumulated amortization	-	-	-	-
Non currrent assets other	-	-	-	-
Deferred long term asset charges	-	-	-	-
Non current assets total	0.26M	-	-	-
Capital lease obligations	0.07M	-	-	-
Long term debt total	-	0.00000M	0.00000M	0.06M

Breakdown	2025-09-30	2024-09-30	2023-09-30	2022-09-30
Type	yearly	yearly	yearly	yearly
Date	2025-09-30	2024-09-30	2023-09-30	2022-09-30
Investments	-0.05750M	-	-	-
Change to liabilities	-	-	-	-
Total cashflows from investing activities	-	0.00000M	0.76M	-
Net borrowings	-0.05446M	-	-	-
Total cash from financing activities	1.00M	1.51M	0.12M	0.14M
Change to operating activities	-	-	-	-
Net income	-1.19320M	-1.29464M	-6.52039M	-0.14578M
Change in cash	-0.15135M	0.85M	0.57M	0.00432M
Begin period cash flow	1.50M	-	-	-
End period cash flow	1.35M	-	-	-
Total cash from operating activities	-0.86235M	-0.65792M	-0.30320M	-0.13569M
Issuance of capital stock	0.00000M	-	-	-
Depreciation	0.08M	0.00004M	0.00005M	0.00006M
Other cashflows from investing activities	-	0.00000M	0.76M	-
Dividends paid	-	-	-	-
Change to inventory	-	-	-	-
Change to account receivables	-	-	-	-
Sale purchase of stock	-	1.55M	-	0.00000M
Other cashflows from financing activities	-	-0.00750M	-	-
Change to netincome	-	-	-	-
Capital expenditures	0.22M	0.00000M	0.00000M	0.00000M
Change receivables	-	-	-	-
Cash flows other operating	-	-	-	-
Exchange rate changes	-	-	-	-
Cash and cash equivalents changes	-	-	-	-
Change in working capital	0.06M	-0.06280M	0.04M	-0.01445M
Stock based compensation	0.17M	-	-	-
Other non cash items	0.01M	-	-	-
Free cash flow	-1.07850M	-	-	-

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company	Change (CAD)	Price (CAD)	Trailing PE (x)	Forward PE (x)	Price Sales TTM (x)	Price to Book Value (x)
METX METX	- -%	1.99	-	-	-	72.00
DRUG Bright Minds Biosciences Inc	-0.85 0.90%	94.04	-	-	-	13.50	-0.098
TELI Telescope Innovations Corp.	0.06 7.23%	0.89	-	-	4.32	6.45	4.32	-1.62
DTC Defence Therapeutics Inc	-0.04 7.27%	0.51	-	-	-	89.80	-9.991
LOBE Lobe Sciences Ltd	- -%	0.09	-	-	2.44	15.58	5.75	1.64

Reports Covered

View All

Profile

ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. The company's lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer. It also develops D094 and D099, which are small molecule myeloid targeted prodrug candidates to treat cancer; and myeloid targeting lipid nanoparticles (LNPS) formulations. ME Therapeutics Holdings Inc. was founded in 2014 and is headquartered in Vancouver, Canada.

METX

177 Robson Street, Vancouver, BC, Canada, V6B 0N3

236 516 7714
https://www.metherapeutics.com

Key Executives

Name	Title	Year Born
Dr. Salim Zulifkar Dhanji Ph.D.	CEO & Director	NA
Mr. Jamil Kassam	Corporate Secretary	NA
Mr. Karim F. Lalji M.S., SM	Chief Business Officer	NA
Dr. Salim Zulifkar Dhanji Ph.D.	Founder, CEO & Director	NA
Mr. Quinn Martin C.A., CPA	Chief Financial Officer	1983

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.